Lenka Oplustil OConnor
Overview
Explore the profile of Lenka Oplustil OConnor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petreus T, Cadogan E, Hughes G, Smith A, Pilla Reddy V, Lau A, et al.
Commun Biol
. 2021 Aug;
4(1):1001.
PMID: 34429505
Microphysiological in vitro systems are platforms for preclinical evaluation of drug effects and significant advances have been made in recent years. However, existing microfluidic devices are not yet able to...
2.
Fok J, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven P, Follia V, James N, et al.
Nat Commun
. 2019 Nov;
10(1):5065.
PMID: 31699977
DNA-dependent protein kinase (DNA-PK) is a critical player in the DNA damage response (DDR) and instrumental in the non-homologous end-joining pathway (NHEJ) used to detect and repair DNA double-strand breaks...
3.
Fornari C, Oplustil OConnor L, Pin C, Smith A, Yates J, Cheung S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 Sep;
8(11):858-868.
PMID: 31508894
Haematological toxicity associated with cancer therapeutics is monitored by changes in blood cell count, and their primary effect is on proliferative progenitors in the bone marrow. Using observations in rat...
4.
Young L, Oplustil OConnor L, de Renty C, Veldman-Jones M, Dorval T, Wilson Z, et al.
Cancer Res
. 2019 May;
79(14):3762-3775.
PMID: 31123088
DNA damage checkpoint kinases ATR and WEE1 are among key regulators of DNA damage response pathways protecting cells from replication stress, a hallmark of cancer that has potential to be...
5.
Fornari C, Oplustil OConnor L, Yates J, Cheung S, Jodrell D, Mettetal J, et al.
Clin Pharmacol Ther
. 2018 Apr;
104(4):644-654.
PMID: 29604045
Balancing antitumor efficacy with toxicity is a significant challenge, and drug-induced myelosuppression is a common dose-limiting toxicity of cancer treatments. Mathematical modeling has proven to be a powerful ally in...
6.
Oplustil OConnor L, Rulten S, Cranston A, Odedra R, Brown H, Jaspers J, et al.
Cancer Res
. 2016 Aug;
76(20):6084-6094.
PMID: 27550455
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of...